EMEA issues guidelines on Alzheimer's and Parkinson's trials
This article was originally published in Scrip
New European guidelines which set out how disease modification might be demonstrated for experimental medicines for Alzheimer's disease and Parkinson's disease have been issued by the European Medicines Agency (EMEA).
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.